Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2001 and is headquartered in New York, New York.

Anavex Life Sciences Corp.

Anavex Life Sciences ( ($AVXL) ) has shared an announcement. On May 20, 2026, Anavex Life Sciences received a delinquency notification from Nasdaq ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVXL	$2.94	+6.52%	1.42M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVXL	$2.94	+6.5%	1.42M
3
4
5
6

AVXL

AVXL

Get Anavex Life Sciences Corp. Data in Excel

Get Anavex Life Sciences Corp. Data in Excel